Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China

Emerging Infectious Diseases

Volumn 23, Issue 5, 2017, Pages 765-772

  Cui, Fuqiang ^a   Shen, Lipin ^b   Li, Li ^b   Wang, Huaqing ^b   Wang, Fuzhen ^b   Bi, Shengli ^b   Liu, Jianhua ^c   Zhang, Guomin ^b   Wang, Feng ^b   Zheng, Hui ^b   Sun, Xiaojin ^b   Miao, Ning ^b   Yin, Zundong ^b   Feng, Zijian ^b   Liang, Xiaofeng ^b   Wang, Yu ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; BIOLOGICAL MARKER; HEPATITIS B VACCINE;

ARTICLE; CHINA; CHRONIC HEPATITIS B; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; ENZYME IMMUNOASSAY; HEALTH CARE POLICY; HEALTH CARE SURVEY; HUMAN; MORBIDITY; MORTALITY; PERINATAL CARE; POPULATION; PREVALENCE; SEROPREVALENCE; VACCINATION; ADOLESCENT; ADULT; CHILD; FEMALE; HEALTH SURVEY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTORY; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; VACCINATION; YOUNG ADULT;

EID: 85018642423     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2305.161477     Document Type: Article

References (46)

1. World Health Organization. Hepatitis B [cited 2015 Nov 16]. http://www.who.int/mediacentre/factsheets/fs204/en
2. Li Y. Epidemiology of virus hepatitis in China. Chinese Journal of Microbiology and Immunology. 1986;Suppl (Viral Hepatitis):1–14.
3. Dai Z, Qi G. Virus hepatitis in China: seroepidemiological survey in Chinese population (part one) 1992–1995. Beijing: Beijing Science and Technology Literature Press; 1996. p. 8–103.
4. Qu Z. Epidemiological study on the distribution of HBsAg and anti-HBs in China. Chinese Journal of Microbiology and Immunology. 1986;Suppl (Viral Hepatitis):20–40.
5. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis. 2009;200:39–47. http://dx.doi.org/10.1086/599332
6. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–25. http://dx.doi.org/10.1093/epirev/mxj009
7. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–7. http://dx.doi.org/10.1016/j.vaccine.2009.08.048
8. Chinese Center for Disease Control and Prevention. China news: viral hepatitis special report [in Chinese] [cited 2016 Aug 6]. http://www.chinacdc.cn/ztxm/zgxwlhtkjkzj/2015nd/201503/P020150305286602526698.pdf
9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55. http://dx.doi.org/10.1016/S0140-6736(15)61412-X
10. Chinese Ministry of Health. Circular on printing and issuing the 2006–2010 National Hepatitis B Prevention and Control Plan. Chinese Practical Journal of Rural Doctor. 2006;13(8):1–5.
11. Kane MA, Hadler SC, Lee L, Shapiro CN, Cui F, Wang X, et al. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. Vaccine. 2013;31(Suppl 9):J15–20. http://dx.doi.org/10.1016/j.vaccine.2013.03.045
12. Liang X, Cui F, Hadler S, Wang X, Luo H, Chen Y, et al. Origins, design and implementation of the China GAVI project. Vaccine. 2013;31(Suppl 9):J8–14. http://dx.doi.org/10.1016/j.vaccine.2012.12.019
13. Wang AL, Qiao YP, Wang LH, Fang LW, Wang F, Jin X, et al. Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China. Bull World Health Organ. 2015;93:52–6. http://dx.doi.org/10.2471/BLT.14.139626
14. Chinese Ministry of Health. The implementation plan of prevention mother-to-child transmission of AIDS, syphilis, and hepatitis B program [in Chinese] [cited 2015 Nov 16]. http://www.nhfpc.gov.cn/zwgkzt/wsbysj/201102/50740.shtml
15. Chinese National Health and Family Planning Commission. Notification of implementing prevention of mother-to-child transmission of HIV, syphilis, and hepatitis B work nationwide [in Chinese] [cited 2015 Nov 20]. http://www.nhfpc.gov.cn/fys/s3581/201506/4f2123fa955a44afa75a75da2ad35d6e.shtml
16. Yang G, Zheng X, Zeng G, Wang B, Zhang Y. Selection of disease surveillance points in second stage and their presentation [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 1992;13:197–201.
17. Zhou M, Jiang Y, Huang Z, Wu F. Adjustment and representativeness evaluation of national disease surveillance points system [in Chinese]. Disease Surveillance. 2010;25:239–44.
18. Yang GH, Zhou MG, Huang ZJ, Wang LJ. Study on the trend and disease burden of injury deaths in Chinese population, 1991–2000 [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:193–8.
19. Xia G, Liu C, Cao H, Bi S, Zhan M, Su C, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nation-wide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun. 1996;5:62–73. http://dx.doi.org/10.1016/S0928-4346(96)82012-3
20. Chinese Center for Disease Control and Prevention; Ministry of Health. The national report of hepatitis B serosurvey in China [in Chinese]. Beijing: People’s Medical Publishing House; 2011. p. 1–102.
21. Hadler SC, Fuqiang C, Averhoff F, Taylor T, Fuzhen W, Li L, et al. The impact of hepatitis B vaccine in China and in the China GAVI Project. Vaccine. 2013;31(Suppl 9):J66–72. http://dx.doi.org/10.1016/j.vaccine.2013.03.043
22. Qu Z. An epidemiological study on the distribution of HBsAg and anti-HBs in China. Chinese Journal of Microbiology and Immunology. 1986;6:S20–40.
23. Wu Z, Cui F, Chen Y, Miao N, Gong X, Luo H, et al. Evaluation of immunization injection safety in China, 2010: achievements, future sustainability. Vaccine. 2013;31(Suppl 9):J43–8. http://dx.doi.org/10.1016/j.vaccine.2012.11.057
24. Cui F, Zhuang H. Hepatitis B control in China: progress, challenges, and strategies. Chinese Journal of Viral Disease. 2016;6:81–7.
25. Liang P, Zu J, Yin J, Li H, Gao L, Cui F, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992–2006: a mathematical model analysis. J Theor Biol. 2015;386:115–21. http://dx.doi.org/10.1016/j.jtbi.2015.08.030
26. Tang S, Meng Q, Chen L, Bekedam H, Evans T, Whitehead M. Tackling the challenges to health equity in China. Lancet. 2008; 372:1493–501. http://dx.doi.org/10.1016/S0140-6736(08)61364-1
27. National Bureau of Statistical of the People’s Republic of China. China statistical yearbook [cited 2016 Feb 16]. http://wwwstatsgovcn/tjsj/ndsj
28. Dang R, Zhang S, Zhang W. Liang X, Cui F, Zhao F. Assessment for immune effectiveness of hepatitis B vaccination among infant population in China. Chinese Journal of Public Health. 2009;25:385–8.
29. Zhang SX, Dang RB, Zhang WD, Liang XF, Cui FQ. Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2008; 29:1003–8.
30. Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51:405–14. http://dx.doi.org/10.1002/hep.23310
31. Cui F, Liang X, Gong X, Chen Y, Wang F, Zheng H, et al. Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. Vaccine. 2013;31(Suppl 9):J29–35. http://dx.doi.org/10.1016/j.vaccine.2012.07.048
32. Cui J, Cao, Zheng J, Cao L, Yuan P, Li L. Coverage analysis of national immunization program vaccine reported in China, 2013 [in Chinese]. Chinese Journal of Vaccines and Immunization. 2015;21:289–95.
33. Li Z, Hou X, Cao G. Is mother-to-infant transmission the most important factor for persistent HBV infection? Emerg Microbes Infect. 2015;4:e30. http://dx.doi.org/10.1038/emi.2015.30
34. Kang W, Ding Z, Shen L, Zhao Z, Huang G, Zhang J, et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China. Vaccine. 2014;32:3362–6. http://dx.doi.org/10.1016/j.vaccine.2014.04.045
35. Wang F, Zheng H, Zhang G, Ding Z, Li F, Zhong G, et al. Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China. Hum Vaccin Immunother. 2015;11:2061–7. http://dx.doi.org/10.1080/21645515.2015.1023972
36. Cui F, Wang F, Zheng H, Chen Y, Li J, Gong X, et al. Evaluation on protective efficacy of recombinant yeast derived hepatitis B vaccine in preventing mother-to-infant transmission of hepatitis B [in Chinese]. Chinese Journal of Vaccines and Immunization. 2007;13:289–93.
37. Wang F, Cui F, Zheng H, Chen Y, Li J, Gong X, et al. Evaluation on protective efficacy of recombinant yeast derived hepatitis B vaccines combination with hepatitis B immune globulin in preventing mother-to-infant transmission of hepatitis B virus [in Chinese]. Chinese Journal of Vaccines and Immunization. 2007;13:293–8.
38. Ionescu-Matiu I, Sanchez Y, Fields HA, Dreesman GR. Development of sensitive immunoassays for detection of antibodies against hepatitis B surface antigen. J Virol Methods. 1983;6:41–52. http://dx.doi.org/10.1016/0166-0934(83)90066-6
39. Deng C, Deng H-P. Comparison of solid phase and colloidal gold method in determination of five serological markers of hepatitis B. Practical Preventive Medicine. 2011;8:2193–4.
40. Chen B, Zhang JM, Jiang Z, Shao J, Jiang T, Wang Z, et al. Media and public reactions toward vaccination during the “hepatitis B vaccine crisis” in China. Vaccine. 2015;33:1780–5. http://dx.doi.org/10.1016/j.vaccine.2015.02.046
41. Yu W, Liu D, Zheng J, Liu Y, An Z, Rodewald L, et al. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China. Int J Epidemiol. 2016;45:441–9. https://dx.doi.org/10.1093/ije/dyv349
42. Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63:319–33. https://dx.doi.org/10.1002/hep.28302
43. Liu Y, Wang M, Yao S, Yuan J, Lu J, Li H, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus. Hepatol Res. 2016;46:E181–8. https://dx.doi.org/10.1111/hepr.12525
44. Zheng H, Wang FZ, Zhang GM, Cui FQ, Wu ZH, Miao N, et al. An economic analysis of adult hepatitis B vaccination in China. Vaccine. 2015;33:6831–9. http://dx.doi.org/10.1016/j.vaccine.2015.09.011
45. Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016;16:80–6. http://dx.doi.org/10.1016/S1473-3099(15)00218-2
46. Zou H, Chen Y, Duan Z, Zhang H. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. PLoS One. 2011; 6:e26748–55. http://dx.doi.org/10.1371/journal.pone.0026748